Literature DB >> 24869748

Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.

Masayuki Sakiyama1, Hirotaka Matsuo, Yuzo Takada, Takahiro Nakamura, Akiyoshi Nakayama, Tappei Takada, Shin-Ichiro Kitajiri, Kenji Wakai, Hiroshi Suzuki, Nariyoshi Shinomiya.   

Abstract

ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP) is a xenobiotic transporter and also regulates serum uric acid levels as a urate transporter. We have shown that the severity of ABCG2 dysfunction can be estimated by simple genotyping of two dysfunctional variants, Q126X (rs72552713) and Q141K (rs2231142). This genotyping method is widely accepted for the risk analysis of hyperuricemia/gout, but there is no report on ethnic differences in ABCG2 dysfunctions. Here, we estimated ABCG2 dysfunctions by its genotype combination (Q126X and Q141K) and compared them in three different ethnic groups (500 Japanese, 200 Caucasians and 100 African-Americans). The minor allele frequencies of Q126X and Q141K in Japanese (0.025 and 0.275, respectively) were significantly higher than those in Caucasians (0.005 and 0.085, respectively) and African-Americans (0 and 0.090, respectively). Additionally, the rates of mild, moderate and severe ABCG2 dysfunctions in Japanese (35.4%, 12.4% and 1.6%, respectively) were higher than those in Caucasians (14.0%, 2.5% and 0%, respectively) and African-Americans (14.0%, 2.0% and 0%, respectively). Because ABCG2 dysfunctional diplotypes were commonly observed in both Caucasians (16.5%) and African-Americans (16.0%), the genotyping of the two ABCG2 dysfunctional variants is useful for evaluating individual differences in the ABCG2 dysfunction which affect the pharmacokinetics of substrate drugs and hyperuricemia risk in all three ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24869748     DOI: 10.2133/dmpk.DMPK-14-SC-041

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  12 in total

1.  Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.

Authors:  Iva Klarica Domjanović; Mila Lovrić; Vladimir Trkulja; Željka Petelin-Gadže; Lana Ganoci; Ivana Čajić; Nada Božina
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

Review 2.  The systems biology of uric acid transporters: the role of remote sensing and signaling.

Authors:  Sanjay K Nigam; Vibha Bhatnagar
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-07       Impact factor: 2.894

3.  Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors.

Authors:  Stephanie R Moulin; Marcelo P Baldo; Juliana B Souza; Weverton M Luchi; Daniel P Capingana; Pedro Magalhães; José G Mill
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-30       Impact factor: 3.738

4.  Porphyrin accumulation in humans with common dysfunctional variants of ABCG2, a porphyrin transporter: potential association with acquired photosensitivity.

Authors:  Masayuki Sakiyama; Hirotaka Matsuo; Yu Toyoda; Yuiko Yonekura; Takahiro Ishikawa; Akiyoshi Nakayama; Toshihide Higashino; Yusuke Kawamura; Norihiro Fujimoto; Nariyoshi Shinomiya; Takahiro Satoh
Journal:  Hum Cell       Date:  2021-05-19       Impact factor: 4.174

5.  Multiple common and rare variants of ABCG2 cause gout.

Authors:  Toshihide Higashino; Tappei Takada; Hirofumi Nakaoka; Yu Toyoda; Blanka Stiburkova; Hiroshi Miyata; Yuki Ikebuchi; Hiroshi Nakashima; Seiko Shimizu; Makoto Kawaguchi; Masayuki Sakiyama; Akiyoshi Nakayama; Airi Akashi; Yuki Tanahashi; Yusuke Kawamura; Takahiro Nakamura; Kenji Wakai; Rieko Okada; Ken Yamamoto; Kazuyoshi Hosomichi; Tatsuo Hosoya; Kimiyoshi Ichida; Hiroshi Ooyama; Hiroshi Suzuki; Ituro Inoue; Tony R Merriman; Nariyoshi Shinomiya; Hirotaka Matsuo
Journal:  RMD Open       Date:  2017-08-29

6.  Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.

Authors:  Yu Toyoda; Andrea Mančíková; Vladimír Krylov; Keito Morimoto; Kateřina Pavelcová; Jana Bohatá; Karel Pavelka; Markéta Pavlíková; Hiroshi Suzuki; Hirotaka Matsuo; Tappei Takada; Blanka Stiburkova
Journal:  Cells       Date:  2019-04-18       Impact factor: 6.600

7.  The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.

Authors:  Blanka Stiburkova; Katerina Pavelcova; Marketa Pavlikova; Pavel Ješina; Karel Pavelka
Journal:  Arthritis Res Ther       Date:  2019-03-20       Impact factor: 5.156

8.  Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.

Authors:  Hirotaka Matsuo; Tomoyuki Tsunoda; Keiko Ooyama; Masayuki Sakiyama; Tsuyoshi Sogo; Tappei Takada; Akio Nakashima; Akiyoshi Nakayama; Makoto Kawaguchi; Toshihide Higashino; Kenji Wakai; Hiroshi Ooyama; Ryota Hokari; Hiroshi Suzuki; Kimiyoshi Ichida; Ayano Inui; Shin Fujimori; Nariyoshi Shinomiya
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

Review 9.  Recent advances on uric acid transporters.

Authors:  Liuqing Xu; Yingfeng Shi; Shougang Zhuang; Na Liu
Journal:  Oncotarget       Date:  2017-08-10

10.  Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.

Authors:  Soo Hyeon Bae; Wan-Su Park; Seunghoon Han; Gab-Jin Park; Jongtae Lee; Taegon Hong; Sangil Jeon; Dong-Seok Yim
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.